Table 1 |
|||||||||||
|
Study Patient Characteristics |
|||||||||||
|
Authors (reference) |
Pub. Date |
Average patient age (years) |
Per cent Male |
BSCr (mg/dl) |
Diabetes (%) |
Contrast volume (ml) |
Jadad Score |
End point (SCr rise) |
Contrast procedure |
NAC regimen |
Hydration regimen |
|
|
|||||||||||
|
Tepel et al. [10] |
07/00 |
65 |
NA |
2.5 |
32.5 |
75 |
1 |
0.5 mg/dl 48 h |
CT |
600 mg tablet bid × 4 |
0.45% 1 ml/kg/h 12 h before, 12 h after |
|
Diaz-Sandoval et al. [11] |
02/02 |
73 |
80% |
1.6 |
38.9 |
184 |
2 |
0.5 mg/dl or 25% 48 h |
LHC |
600 mg liquid in ginger ale bid × 4 |
0.45% 1 ml/kg/h 2–12 h before, 12 h after |
|
Briguori et al. [12] |
07/02 |
64 |
86% |
1.5 |
37.8 |
197 |
1 |
25% 48 h |
LHC and/or PA and/or PCI |
600 mg tablet bid × 4 |
0.45% 1 ml/kg/h 12 h before, 12 h after |
|
Vallero et al. [13] |
09/02 |
62 |
NA |
1.0 |
23.0 |
205 |
1 |
0.5 mg/dl or 33% 48 h |
LHC and/or PCI |
600 mg tablet bid × 4 |
0.45% 1 ml/kg/h 1–2 h before, 24 h after |
|
Shyu et al. [14] |
10/02 |
70 |
68% |
2.8 |
63.5 |
117 |
1 |
0.5 mg/dl 48 h |
LHC ± PCI |
400 mg powder bid × 4 |
0.45% 1 ml/kg/h 12 h before, 12 h after |
|
Allaqaband et al. [15] |
11/02 |
70 |
NA |
2.1 |
48.3 |
122 |
3 |
0.5 mg/dl 48 h |
LHC ± PCI or PA + PCI |
600 mg liquid in cola bid × 4 |
0.45% 1 ml/kg/h 12 h before, 12 h after |
|
Durham et al. [16] |
12/02 |
71 |
66% |
2.3 |
48.1 |
81 |
3 |
0.5 mg/dl 48 h |
LHC |
1200 mg liquid in orange juice bid × 2 |
0.45% 1 ml/kg/h ≤ 12 h before, ≤ 12 h after |
|
Kay et al. [17] |
02/03 |
69 |
62% |
1.3 |
37.5 |
125 |
5 |
25% 48 h |
LHC and/or PCI |
600 mg tablet bid × 4 |
0.9% 1 ml/kg/h 12 h before, 6 h after |
|
Loutrianakis et al. [18] |
03/03 |
67 |
NA |
1.9 |
36.0 |
147 |
1 |
0.5 mg/dl 120–168 h |
LHC |
600 mg bid × 4 |
0.45% 1 ml/kg/h |
|
Azmus et al. [19] |
07/03 |
67 |
59% |
1.3 |
49.6 |
126 |
5 |
0.5 mg/dl or 25% 24–48 h |
LHC or PCI |
600 mg powder in water bid × 5 |
0.9% 1 L pre, 1 L post, or none |
|
Gomes et al. [20] |
10/03 |
65 |
59% |
1.3 |
51.9 |
103 |
4 |
0.5 mg/dl 48 h |
LHC or PCI |
600 mg bid × 4 |
0.9% 1 ml/kg/h 12 h before, 12 h after |
|
Nguyen-Ho et al. [21] |
11/03 |
70 |
NA |
1.4 |
67.5 |
347 |
4 |
25% 48–72 h |
LHC or PCI |
2000 mg liquid in juice bid × 2 or 3 |
0.45% 75 ml/h ≥ 24 h from enroll |
|
Efrati et al. [22] |
12/03 |
67 |
90% |
1.5 |
52.9 |
140 |
2 |
25% 24–96 h |
LHC |
1000 mg liquid in cola bid × 4 |
0.45% 1 ml/kg/h |
|
El Mahmoud et al. [23] |
12/03 |
67 |
81% |
1.9 |
30.0 |
177 |
2 |
25% 24–48 h |
LHC |
600 mg orally bid × 2 |
0.9% 1 ml/kg/h |
|
Kefer et al. [24] |
12/03 |
62 |
77% |
1.1 |
12.5 |
199 |
1 |
0.5 mg/dl or 25% 24 h |
LHC and/or PCI |
1200 mg in 0.9% saline IV over 60 min, 12 h pre 0 h post |
0.9% 1 ml/kg/h |
|
MacNeill et al. [25] |
12/03 |
73 |
86% |
1.9 |
46.5 |
110 |
4 |
25% 72 h |
LHC ± PCI |
600 mg liquid in juice/soda bid ×5 |
0.45% 1 ml/kg/h 12 h or 2 ml/kg/h 4 h before, 75 ml/h 12 h after |
|
Oldemeyer et al. [26] |
12/03 |
76 |
55% |
1.6 |
44.9 |
131 |
2 |
0.5 mg/dl or 25% 48 h |
LHC |
1500 mg liquid in soda bid × 4 |
500 ml D5 20 ml/h 12 h before, 12 h after |
|
Goldenberg et al. [27] |
02/04 |
70 |
83% |
2.0 |
43.9 |
116 |
5 |
0.5 mg/dl 48 h |
LHC ± PCI |
600 mg liquid in soda tid × 6 |
0.45% 1 ml/kg/h |
|
Agrawal et al. [28] |
04/04 |
63 |
68% |
1.7 |
47.8 |
178 |
2 |
0.5 mg/dl or 25% 48 h |
LHC and/or PCI |
800/600/600 mg liquid in soda 12/2 h pre/6 h post |
0.45% 1 ml/kg 12 h ± 250 ml bolus before, 12 h after |
|
Fung et al. [29] |
05/04 |
68 |
70% |
2.3 |
52.8 |
128 |
3 |
0.5 mg/dl or 25% decrease in GFR 48 h |
LHC or PCI ± PA |
400 mg powder tid × 6 |
0.9% 100 ml/h 12 h before, 12 h after |
|
Ochoa et al. [30] |
06/04 |
71 |
43% |
2.0 |
55.5 |
144 |
4 |
0.5 mg/dl or 25% 48 h |
LHC and/or PCI |
1000 mg liquid in diet cola bid × 2 |
0.9% 150 ml/h, ≥ 500 ml 12 h before, ≥ 1000 24 h after |
|
Webb et al. [31] |
09/04 |
70 |
NA |
1.7 |
34.9 |
120 |
5 |
0.5 mg/dl 48–192 h |
LHC or PCI ± PA |
500 mg in D5NS IV for 15 min, 1 h pre |
0.9% 200 ml before, 1.5 ml/kg/h 6 h or discharge (<6 h) after |
|
|
|||||||||||
|
SCr, serum creatinine; BSCr, baseline serum creatinine; CT, computed tomography; LHC, left heart catheterization; PCI, percutaneous coronary intervention; PA, peripheral angiography; Jadad score, measure of study design quality (0 is the weakest, 5 is the strongest); NAC, N-acetylcysteine; NA, not applicable; bid, twice daily; tid, three times daily; IV, intravenous; h, hour; D5NS, 5% dextrose plus normal saline; 0.9%, normal saline; 0.45%, half-normal saline. |
|||||||||||
|
Gonzales et al. BMC Medicine 2007 5:32 doi:10.1186/1741-7015-5-32 |
|||||||||||
